Key result
Apolipoprotein CIII acts as an inhibitor of lipoprotein lipase and triglyceride-rich lipoprotein uptake, and its absence results in a dramatic increase in lipolysis of VLDL-TG.
Answers are grounded in this paper and cite their sources.
ApoCIII is a complex apolipoprotein that inhibits lipoprotein lipase and the hepatic uptake of triglyceride-rich lipoproteins.
Apolipoprotein (apo)CIII, comprised of 79 amino acids and with a mass of 8.8 kDa, was first isolated and characterized 50 years ago by Brown et al. (1). Studies conducted during the following decade demonstrated that apoCIII was an inhibitor of both LPL (2) and the uptake of triglyceride-rich lipoproteins (TGRLs) and remnants by perfused livers (3, 4). Lipoprotein kinetic studies of two sisters with complete absence of apoCIII (5) demonstrated, in vivo, that absence of this protein resulted in a dramatic increase in lipolysis of VLDL-TG (6).
No takes yet. Share an insight, caveat, or question.
Reyes‐Soffer et al. (2019) reported an editorial. Apolipoprotein CIII was evaluated. Apolipoprotein CIII acts as an inhibitor of lipoprotein lipase and triglyceride-rich lipoprotein uptake, and its absence results in a dramatic increase in lipolysis of VLDL-TG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: